STAT Wunderkinds: 5 years of progress
STAT is joined by a group of the first Wunderkinds class to discuss their experiences and lessons learned since joining their cohort in 2017.
STAT is joined by a group of the first Wunderkinds class to discuss their experiences and lessons learned since joining their cohort in 2017.
Health plans, in collaboration with their members, the medical community, and others, can make meaningful reductions in health inequities.
Lilly’s data on an experimental Alzheimer’s drug and its ability to clear amyloid plaques came under question by experts at the STAT Summit.
Research institutions and biotech companies are generating more data than ever, but there just aren’t enough data scientists.
The FDA approved the first treatment for the most common cause of dwarfism Friday, a drug that has proved to increase children’s height.
A proposal for the WTO to temporarily waive intellectual property rights and widen access to Covid-19 products appears unlikely to pass.
This Genome Watch highlights how the SARS-CoV-2 pandemic laid the groundwork for continued use of real-time genomic epidemiology for public health responses in low-and-middle-income countries.
DART mission is first to try out a strategy for shielding the planet from killer asteroids.
In preliminary testing, the wearable identified infections in open wounds before they looked any different than uninfected wounds.
An open letter signed by 145 female scientists from across the world expresses concern over recent dismissals of women leaders